Study finds each hour spent watching TV daily increases the risk of developing diabetes by 3.4 percent

 

Pittsburgh, PA, USA (April 1, 2015) – Each hour spent watching TV daily increases the risk of developing diabetes by 3.4%, concludes a study published in Diabetologia (the journal of the European Association for the Study of Diabetes). The study, on the effects of sedentary or ’sitting‘ time on diabetes risk, is by Dr Bonny Rockette-Wagner (lead author) and Dr Andrea Kriska (senior author) from the University of Pittsburgh, PA, USA, and colleagues.


In this new research, the authors used data from participants in the Diabetes Prevention Program (DPP) study (published in 2002 and funded by the National Institute of Digestive and Diabetes and Kidney Diseases [NIDDK] section of the US National Institutes of Health [NIH]). That study enrolled 3,234 overweight US adults (1996-1999) of at least 25 years of age with the goal of delaying or preventing type 2 diabetes in high risk individuals with either a metformin drug or lifestyle intervention. Previous work has already suggested that the lifestyle intervention was successful at reducing the incidence of diabetes and achieving its goals of 7% weight loss and 150 minutes per week of moderate intensity activity (such as brisk walking).

 

What is not known is whether this lifestyle intervention effort had any impact on time spent sitting (being sedentary). Previous results suggest that it is unclear if interventions focusing on increasing physical activity also reduce time spent sitting. This new study examined whether the DPP lifestyle intervention, which was shown to be effective at increasing physical activity, also decreased self-reported sitting time. The effect of sedentary behaviour on diabetes development was also examined.

 

Prior to the intervention, total time spent watching TV was not found to be significantly different between the placebo, metformin, and lifestyle groups of DPP (around 140 minutes per day in all three groups). The daily total of time spent sitting at work plus TV time was also not significantly different across groups (between 410 and 423 minutes per day) when the study began.

 

For the lifestyle participants, a reduction in reported TV watching time throughout follow-up was observed for all participant subgroups including age, sex, work status, race/ethnicity, obesity status, or those achieving the weight and/or activity goal(s). Similarly, the lifestyle group had the greatest reduction in mean time spent in TV watching time plus time sitting at work during follow-up. The combined average reduction in TV watching and time sitting at work was 9, 6, and 37 min/day for the placebo, metformin and lifestyle groups respectively.

 

The authors then investigated the impact of sedentary behaviour over time on diabetes incidence. For participants in all treatment arms, the risk of developing diabetes increased approximately 3.4% for each hour spent watching TV after adjustment for age, sex, treatment arm and time-dependent leisure physical activity. This association was reduced when time-dependent weight was added to the model (to a 2.1% increased risk of developing diabetes per hour of watching TV, which was not statistically significant) suggesting that subsequent changes in body weight may account for some of the relationship between sitting behaviour changes and diabetes development.

 

"These findings are particularly noteworthy because a decrease in sitting occurred despite the absence of programme goals aimed at reducing sitting," said senior author, Dr Kriska. "It is likely that a lifestyle intervention programme that incorporates a specific goal of decreasing sitting time would result in greater changes in sitting and likely more health improvements than are demonstrated here. Finally, these results should inform future intervention efforts that already focus on goals of increasing activity and reducing weight to also consider emphasising sitting less."

 


Diabetologia (the journal of the European Association for the Study of Diabetes), 01.04.2015

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…